

## **genOway announces important framework agreement with UPenn (University of Pennsylvania) one of the top ten U.S universities**

**Lyon, France – November 4, 2009** - genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports an important framework agreement with the University of Pennsylvania (USA).

After an international competition, the company has been selected for a framework contract of a two years renewable period.

Through this agreement, researchers at the University of Pennsylvania whose prestigious areas of study cover neurosciences, heart disease and metabolic disorders will benefit from the expertise gained by genOway in transgenic technology and technological innovations developed by the Company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified models of mice and rats.

Financial terms of the agreement were not disclosed.

**Alexandre Fraichard, CEO of genOway, declared:** *« We are very pleased to become, after an international competition, the supplier of the University of Pennsylvania whose research excellence is internationally renowned. Our technologies fully meet the growing needs of its academic researchers and this agreement perfectly demonstrates the very strong commercial dynamic that we encounter with academic centers. Our growth in 2010 and 2011 will come from these agreements with academic centers combined to those reached with pharmaceutical companies. We should sign before the end of the year, at least two more framework agreements with research centers of excellence and renew one of our major pharmaceutical partnership. »*

### **About The University of Pennsylvania (UPenn)**

The University of Pennsylvania is a university with more than 24 000 students and more than 4 500 researchers. It contains research centers among the most efficient in the world like The Mahoney Institute of Neurological Sciences (MINS). It is considered one of the top ten U.S. Universities and has a research budget of 730 million dollars.

### **About genOway**

genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, supplying more than 275 customers. genOway is a leader in its market in terms of both size and customer portfolios. The company's development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King's College and the University of Manchester, in England; Duke University and the National Institutes of Health, in the United States; the Institut Pasteur, in France; NGFN and the Max Planck Institutes, in Germany, etc.). To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents).

For more information please go to [www.genoway.com](http://www.genoway.com).

**Press relations:** Marie Norbert - genOway - [info@genoway.com](mailto:info@genoway.com)

**Contact for investors:** Gaëlle Lebel , CFO – [info@genoway.com](mailto:info@genoway.com)

**Milestones - press & investor relations:** Bruno Arabian / Jacques-Olivier Costa  
Tel.: +33 (0)1 75 44 87 40 / 42 – E-mail: [barabian@milestones.fr](mailto:barabian@milestones.fr) / [jocosta@milestones.fr](mailto:jocosta@milestones.fr)

*Warning: This press release contains certain prospective statements, either express or implied, concerning genOway and its activities. These statements rely on certain risks, either known or unknown, uncertainties or other factors, that may lead to genOway's actual results, financial condition, performance or achievements differing significantly from the results, financial condition, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to updating the prospective statements contained therein, either as a result of new information, future events or any other occurrence. For a detailed description of the types of risks or uncertainties likely to cause a difference between genOway's actual results, financial condition, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" in the prospectus available on the genOway website: [www.genoway.com](http://www.genoway.com).*